Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious disease, said its chief executive and chief scientific officer, professor Lindy Durrant, will present at the 2023 World Vaccine Congress Europe, currently underway in Barcelona.
Durrant said: "Following the recent announcement of positive data from the first stage in our phase II SCOPE trial with SCIB1 cancer vaccine for advanced melanoma, I am excited to join other leading experts in the field to discuss the ongoing clinical progress of our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum within the vaccine community."